Clinical Trial Update: Precise Design of Cell Therapy for Relapsed and Refractory Hematological Tumors [NA]

View source ↗

Summary

This clinical trial update outlines the precise design of a cell therapy approach for relapsed and refractory hematologic tumors, sponsored by Ruijin Hospital, …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hematologic Malignancies

Snippet

Sponsor: Ruijin Hospital | Conditions: Precise Design of Cell Therapy for Relapsed and Refractory Hematological Tumors, Hematologic Disease | NA | Status: ACTIVE_NOT_RECRUITING